Abstract. The epidermal growth factor receptor, EGFR, is overexpressed in many carcinomas. Targeting this receptor with radionuclides is important for imaging and therapy applications in nuclear medicine. We investigated the in vitro and in vivo properties of a new high affinity EGFR binding affibody molecule, (Z EGFR:955 ) 2 , when conjugated with CHX-A''-DTPA and labelled with 111 In. The binding time patterns and retention studies were performed using cultured squamous carcinoma A431 cells that overexpress EGFR. In the in vivo studies, female BALB/c nu/nu mice carrying tumours from xenografted A431 cells were used. The in vitro studies showed EGFR specific binding, high uptake and good retention of 111 In when delivered as [ 111 In](Z EGFR:955 ) 2 . The retention after 72 h of incubation was 38.0±1.15% of the initial level. The biodistribution study showed a tumour specific 111 In uptake of 3.8±1.4% of injected dose per gram tumour tissue 4 h post-injection. The tumour to blood ratio was 9.1 and the tumours could easily be visualized with a gamma camera at this time-point. 111 In delivered with [ 111 In](Z EGFR:955 ) 2 gave an EGFR specific uptake and the results indicated that the (Z EGFR:955 ) 2 affibody molecule is a candidate for radionuclidebased tumour imaging. Potential therapy applications are discussed.
Introduction
Overexpression of epidermal growth factor receptors, EGFR, is common in squamous carcinomas from the cervix, lungs and head and neck region. Some adenocarcinomas, such as colon and ovarian tumours, also express high levels of EGFR as well as gliomas and urinary bladder cancers (1, 2) . Thus, different types of tumours can have high expression of EGFR. It is therefore important to find targeting agents suitable for imaging applications with the purpose to select suitable treatments for the individual patient.
EGFR belongs to a transmembrane tyrosine kinase receptor family. This family which consists of four receptors, EGFR, HER2, HER3 and HER4, regulates many important cellular processes such as proliferation, apoptosis and migration (3) (4) (5) . Receptor activation is dependent on receptor dimerisation and activation triggers autophosphorylation of the kinase domain which starts a signalling cascade, resulting in increased proliferation and decreased apoptosis (3, 6) .
There are presently at least five marketed products designed to target receptors in the EGFR family. These are the monoclonal antibodies trastuzumab, that influence HER2 mediated signal transduction, cetuximab and panitumumab, which blocks EGF from binding to the EGFR receptor (7) (8) (9) , and the tyrosine kinase inhibitors gefitinib and erlotinib, which inhibit the activation of EGFR (10, 11) .
A new category of targeting agents that are interesting for imaging applications is affibody molecules (Affibody ® ) (12) . These molecules are based on 58 amino acid monomers and are derived from the IgG-binding domains of staphylococcal protein A. They are small, 7 or 15 kDa (depending on monomeric or dimeric state), resulting in good tumour penetration and fast blood clearance compared to larger molecules, e.g. antibodies (13, 14) . An anti-HER2 affibody molecule, Z HER2:342 , has been characterized and tested in a few patients (15, 16) . This molecule has been labelled with 111 In for SPECT or 68 Ga for PET and has potential to be used for detection of HER2 expression in primary breast cancers and related metastases. Cell culture. The squamous carcinoma cell line A431 (CRL 1555, LGC-promochem, Borås, Sweden) with high EGFRexpression, was used in all studies. The cells were cultured in Ham's F-10 medium, supplemented with 2 mM L-glutamine, PEST (penicillin 100 IU/ml and streptomycin 100 μg/ml) and 10% fetal calf serum (Biochrom Kg, Berlin, Germany). Such culture medium is from now and on called complete medium.
The cells were cultured in 75 cm 2 culture bottles (Nunclon™ surface, Roskilde, Denmark). The cells were grown at 37˚C in an incubator with humidified air equilibrated with 5% CO 2 .
Radiolabelling. The (Z EGFR:955 ) 2 and the irrelevant (Z abeta3-C28S ) 2 affibody molecules were conjugated to CHX-A''-DTPA in borate buffer (0.07 M pH 9.2) at 37˚C overnight, using initial chelator with a protein molar ratio of 1:1. The conjugated CHX-A''-DTPA-(Z EGFR:955 ) 2 was purified on a NAP-5 size exclusion column (Sephadex G-25, Amersham Biosciences, Uppsala, Sweden), using 0.2 M ammonium acetate buffer pH 5.5 as eluent, and then split into aliquots (which were frozen in -20˚C and later used for chelation). Arbour, MI, USA) eluted with citric acid (0.2 M). The plates were measured on a Cyclone Phosphorimager (Packard, IL, USA) and analysed using OptiQuant image analysis software (Hach Co., Loveland, USA). A CHX-A''-DTPA chelator was selected because it provides both rapid labelling with 111 In at room temperature and high stability in vivo. Our experience (19) showed that of CHX-A''-DTPA suites well for labelling of affibody molecules. 2 was preincubated at 37˚C for 11 h and the cells was washed six times in cold serum-free medium and further incubated with 1 ml fresh complete medium for further 0, 2, 4, 8, 12, 24, 48 and 72 h. After the last incubation the medium was collected and the cells were washed, trypsinised and counted, and the radioactivity was measured as described earlier. Triplicate samples were prepared.
Biodistibution. The local ethics committee for animal research approved the animal studies. Female BALB/c nu/nu mice were injected with ~7x10 6 A431 cells (in 100 μl complete medium) in the right fore leg. Xenografts were allowed to establish during eight days. The mice were then randomly selected into groups each containing four mice. Two groups were injected with 100 μl (1 μg, 0. 2 45 min before the i.v. injection. After 4 h the mice were anaesthetized with a mixture of ketamine and xylazine i.p. The mice were then imaged using a e.CAM (Siemens, Erlangen, Germany) gamma camera equipped with a medium-energy, general-purpose collimator. The images were stored in a 256x256 bit matrix.
Results

Time-dependent cellular uptake. [
111 In](Z EGFR:955 ) 2 gave the highest uptake (3x10 5 CPM/10 5 cells) of 111 In after 12 h of incubation, and ~90% of the cell-associated 111 In remained after 24 h (Fig. 1) . The uptake pattern of 111 In was similar to the 125 I uptake, when delivered as [ 125 I](Z EGFR:955 ) 2 , as described in an earlier study (18) . The cellular binding of the 111 Inlabeled substance could effectively be inhibited by an excess of the corresponding non-labelled substance, confirming specific uptake (data not shown). 2 , was followed up to 8 h in Balb/mice carrying xenografted A431 tumours (Fig. 3) . Four hours p.i. the tumour uptake was 3.8±1.4% ID/g and after 8 h it had decreased to 2.0±0.5% ID/g. The radiotracer had a rapid blood clearance, with a concentration <0.4±0.1% ID/g in the circulation after 4 h at which time the tumour to blood ratio was 9. 2 . The uptake of this control affibody molecule in the tumours was low (Fig. 3 ).
There were high 111 In uptake in the kidneys and liver when delivered with [
111 In](Z EGFR:955 ) 2 . The liver uptake could be blocked by administration of an excess of unlabelled (Z EGFR:955 ) 2 while this was not the case for the kidney uptake. The kidney uptake of 111 In was high also for the irrelevant affibody molecule (Table I) . 2 , as reported in a previous study by Nordberg et al (18) . Mean values and standard deviations are shown. - 2 , was detectable using a gamma camera 4 h after injection (Fig. 4) . The tumour on the right fore leg was visible while no radioactivity could be seen on the contralateral side or in the tumour of the control mouse that in addition to [
111 In]-(Z EGFR:955 ) 2 was pre-injected with an excess of non-radiolabelled (Z EGFR:955 ) 2 , confirming antigen specific tumour uptake.
Discussion
The affibody molecule [
111 In](Z EGFR:955 ) 2 was developed and studied with the aim that it could be a candidate for imaging of EGFR expression in tumours and metastases. Before investigating the binding in vivo it was necessary to characterize the binding in vitro.
The (Fig. 1 ) and initially also a fast release as seen in the retention analysis (Fig. 2) . The quick ligand dissociation during the first 4 h was probably due to [
111 In](Z EGFR:955 ) 2 molecules detaching from the receptors at the cell surface without being internalised. After 4 h, it appeared that another fraction, 38%, of the [ 111 In], was still associated to the cells for at least 72 h. This fraction was probably internalised. Similar retention patterns were also detected in our earlier study (18) performed with the same affibody molecule but labelled with 125 I (Fig. 2) . However, the retention after several hours of incubation was lower in the 125 I case. Radiometals are known to be trapped in lysosomes, resulting in good cellular retention (20, 21) , and this is a reasonable explanation for the higher level of retention of [
111 In] in comparison to 125 I. To analyze the uptake in vivo, a biodistribution study was done (Fig. 3) (22) . The tumour to blood ratio was also compared with the same study and was found to be in good agreement (tumour to blood ratios of 9.1 as compared to 12.1). The tumour to blood ratio were further compared to studies using radiometal-labelled anti-EGFR antibodies or EGF-ligand. When analyzed within 24 h after injection, the affibody showed better tumour-to-blood ratios (9.1) compared to the antibody (1.5) or the natural EGF-ligand (3.0) (23, 24) . The kidneys and liver obtained the highest uptake of [
111 In]. A high kidney uptake is probably a consequence of kidney clearance and tubular reabsorption that is common for small proteins. As radioactive metals are residualizing, the [ 111 In] will be trapped in the kidneys following tubular resorbtion of the labelled affibody molecule (25) . The high liver uptake is most likely due to the normal expression of EGFR in liver tissue (26) and cross-reactivity of [
111 In] (Z EGFR:955 ) 2 with murine EGFR. This is supported by the fact that the liver uptake could be blocked by a factor of ten by administration of an excess of unlabelled (Z EGFR:955 ) 2 , and that the non-specific affibody molecule was not accumulating in the liver. The uptake in the kidneys could not be inhibited this way. Note that the kidney uptake of [
111 In] increased when the uptake in the liver was blocked (Table I) .
The tumours in the right fore leg of the mice were clearly visualized in gamma camera, even though they were quite close to the kidneys and liver, that also gave a strong signal in the gamma camera. Thus, tumour tissue reasonable close to the liver and kidneys in mice can be visualised. An excess amount of unlabeled (Z EGFR:955 ) 2 could block the [
111 In]-(Z EGFR:955 ) 2 mediated gamma camera signal of the tumour, which supported the biodistribution results regarding receptor specificity (Fig. 4) .
Small peptides like somatostatin analogues labelled with 177 Lu have been shown to give therapy effects (27, 28) and it is possible that (Z EGFR:955 ) 2 labelled with 177 Lu also could be of therapeutic interest. However, due to the high liver and kidney uptake the molecule used in this study might only be used through locoregional administration, e.g. for treatment of the urinary bladder carcinoma (29) or gliomas (30) . High molecular weight substances are most likely favourable for therapeutic applications since high renal uptake of radionuclides is avoided, e.g. [
111 In] and 177 Lu, as demonstrated with radiolabelled cetuximab (24) , pertuzumab (31) and albumin-ABD-conjugated affibody molecules (32) . Furthermore, unlabelled (Z EGFR:955 ) 2 might be used therapeutically by blocking EGF-binding to EGFR, in analogy with cetuximab or panitumumab (9 potentially also be used for identification of patients with tumours that are suitable for treatment with EGFR targeting agents, e.g. treatment of non-small cell lung cancer with gefitinib (33) , and for follow-up of such therapy to evaluate if receptors are up-or down-regulated.
